As the popularity of GLP-1 receptor agonists continues to surge in the treatment of obesity and type 2 diabetes, Evofem Bioscie...

This amended and restated Merger Agreement, among others, addresses pre-closing issues critical for Evofem's future success...

-8-K

https://www.washingtonpost.com/world/2024/03/04/france-abortion-constitution/

Laidlaw & Co. analyst Yale Jen downgrades Evofem Biosciences (OTC:EVFM) from Buy to Hold.

Aditxt Inc (NASDAQ: ADTX) has agreed to acquire Evofem Biosciences Inc (OTC: EVFM) in consideration of the issuance of a combin...

Evofem posted $13.4 million in net sales of Phexxifor the first nine months of 2023;Aditxt looks to accelerate Evofem into the ...

-- Padagis Determined They Will Not Challenge the Phexxi Patents --  -- Evofem Has Phexxi Patent Protection Through 2033 -- 

On Thursday May 18, 2023, the Company's common stock will open for trading under a new CUSIP (30048L302) on the OTC Venture...